Please provide your email address to receive an email when new articles are posted on . Disease-modifying therapy de-escalation may be safe in certain older patients with MS. More data are needed to ...

WEST PALM BEACH, Fla. — Discontinuing disease-modifying therapies (DMTs) for multiple sclerosis (MS) after prolonged disease stability poses minimal risk for patients aged > 60 years, highlighting the ...

For the past six decades Medicare has been providing coverage to America’s adults aged 65 and older. Today, roughly 1 in 5 ...

A new study shows Louisiana and Mississippi provide the poorest Medicare access, affordability, and quality for older adults.

The National Institute for Health and Care Excellence (NICE) has recommended ublituximab (Briumvi) for treating people with relapsing remitting multiple sclerosis (MS). The drug should be available ...

A new Commonwealth Fund report paints a stark picture of how Medicare is serving older adults and people with disabilities in ...